Revelation Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Revelation Biosciences

14/08/2023 22:03

* Revelation Biosciences Inc  REVB.OQ  reported a quarterly
adjusted loss of 25 cents​​ per share for the quarter ended in
June. The mean expectation of two analysts for the quarter was
for a loss of 40 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Revelation Biosciences Inc's reported EPS for the quarter
was a
loss of 25 cents​.
    * The mean earnings estimate of analysts had risen by
about 16.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Revelation Biosciences Inc shares had fallen by 20.2% this
quarter and lost 88.7% so far this year.
    * The company reported a quarterly loss of $1.45 million.
    * Wall Street's median 12-month price target for Revelation
Biosciences Inc is $11.45 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.40          -0.25          Beat
 Mar. 31 2023      -0.65          2.79           Beat
 Dec. 31 2022      -1.75          -1.77          Missed
 Sep. 30 2022      -3.15          -2.10          Beat